Kornimate/medical-research-clean huggingface dataset:
candida pcr diagnosis strategy in patients from intensive care units

Conditions: Candida

Summary: the aim of this study is to evaluate the implementation of a new technique for invasive candidiasis diagnosis by pcr. the main objective will be to evaluate the effect of this strategy on the time required to obtain results in patients from intensive care units with suspected systemic invasive candidiasis. this pcr method could allow an antifungal switch to be made earlier, limiting the appearance of resistance and reducing the cost of antifungals for healthcare facilities.

invasive candidiasis is a serious infection caused by yeasts of the genus candida sp. their incidence is increasing, particularly in intensive care. the prognosis is severe and depends on the early initiation of adequate antifungal treatment. at present, the diagnosis of invasive candidiasis is difficult since blood culture, the reference technique, has major limitations due to its low sensitivity, as well as very long delays in obtaining results. as a consequence, suspected invasive candidiasis is often treated empirically with echinocandins, resulting in the development of resistance and extremely high costs for health care facilities. the switch to treatments such as fluconazole is often delayed, although this molecule is effective on most candida species except c. krusei and glabrata and is much less expensive than echinocandins. for these reasons, the present study developed faster and more efficient methods to diagnose candida krusei and glabrata species, based on the detection of dna in the blood by pcr, allowing an earlier switch from echinocandins to fluconazole. the patients included will be divided into 2 groups: one group of patients will benefit from a diagnostic strategy based on blood culture (reference technique for the detection of candida) and another group of patients will benefit from a diagnostic strategy based on this new pcr technique. the main objective will be to evaluate the effect of the pcr strategy on the time to obtain results and on the switch of antifungal agents. after inclusion, patients will be followed up at day 14, day 28 until discharge (or 3 months if the patient is still hospitalised).

Eligibility criteria:
inclusion criteria: * patient affiliated or benefiting from a social protection system * patient (or his/her trusted person) having given free and informed written consent to the investigating physician * non-neutropenic patient hospitalised in the toulouse university hospital intensive care unit. * patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented. exclusion criteria: * patients under guardianship or trusteeship, persons under court protection * pregnant or breastfeeding patients.

Keywords: candidemia polymerase chain reaction dna antifungal agents
risk factors for shoulder joint motion restriction

Conditions: Breast Cancer Survivors

Summary: in breast cancer patients, limitation of shoulder joint movement may occur following cancer treatment. shoulder limitation causes a significant decrease in the patient's participation in activities of daily living. the aim of the study is to define these limitations, to evaluate in detail all the structures that cause the problem, and to determine the causes of the limitations in patients with shoulder joint movement limitation developed after breast cancer survivors.


Eligibility criteria:
inclusion criteria: * women between the ages of 30-60 * having breast cancer treatment within 5 years exclusion criteria: * not having agreed to participate in the study * presence of additional orthopedic (scoliosis, etc.), neurological (multiple sclerosis, stroke, etc.) and rheumatological diseases (ankylosing spondylitis, rheumatoid arthritis, etc.) that will affect upper extremity functions

Keywords: breast cancer range of motion
the effect of blood flow restriction method in patellar instability

Conditions: Patellar Abnormality

Summary: the blood flow restriction method, the effects of which have been frequently investigated in the literature in recent years, can produce muscle hypertrophy with low-intensity load and can be easily tolerated through to low mechanical stress, seems to be an exercise approach that can be used in the recovery of strength in cases with minor patellar instability and can contribute to the recovery of functional capacity without delay.

patellar instability is defined as disruption of normal movement of the patella in the trochlear groove, symptomatic, medial-lateral displacement. patients with patellar instability may not be able to tolerate high-intensity quadriceps exercises in the early period of strengthening programs due to pain symptoms, and therefore strength recovery may be delayed. however, it is important to restore muscle strength, especially vastus medialis obliquus strength, as early as possible in patellar instability. the blood flow restriction method, the effects of which have been frequently investigated in the literature in recent years, can produce muscle hypertrophy with low-intensity load and can be easily tolerated through to low mechanical stress, seems to be an exercise approach that can be used in the recovery of strength in cases with minor patellar instability and can contribute to the recovery of functional capacity without delay.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-40 years, * volunteering to participate in the study, * having a complaint of anterior knee pain for at least 3 months, * having been diagnosed with unilateral minor patellar instability, * absence of any other ongoing clinical problems that interfere with exercise (will be questioned by the physical activity readiness questionnaire for all). exclusion criteria: * history of one or more traumatic-atraumatic patella dislocations, * evidence of osteoarthritis on radiological imaging (≥ kellgren-lawrence stage 2) * having at least one of the contraindications preventing the application of blood flow restrictive exercises (smoking, previous venous thromboembolism, risk of peripheral vascular disease (ankle-brachial index \<0.9), coronary heart disease, hypertension, hemophilia, etc.), * previously diagnosed cardiovascular disease limiting effort capacity (myocardial infarction, angina, exercise intolerance, etc.), * previously diagnosed neurological disorder or cognitive dysfunction (stroke, dementia, schizophrenia, etc.), * orthopedic lower extremity surgery in the last 1 year, * body mass index ≥ 30 kg/m2.
atropine and spectacle combination treatment (aspect): 12-month results of a randomized clinical trial for myopia control

Conditions: Myopia

Summary: phase iv clinical trial to evaluate whether there is a significant difference in the control of myopia progression in myopic children treated with 0.025% atropine and dims spectacle lenses compared to 0.025% atropine and single vision (sv) lenses. open-label, randomized, parallel clinical trial with 2 arms, involving 111 patients in total. the primary efficacy endpoint will be the change in cycloplegic spherical equivalent refraction (ser) and axial length (al) compared to baseline values.


Eligibility criteria:
inclusion criteria * age between 4-16 years. * signing of informed consent. * refractive error: myopia greater than -1.00 diopters (d). * myopia progression of at least -0.50 d in the last 12 months. * astigmatism of 2 d or less and anisometropia of 1.50 d or less. * best-corrected monocular visual acuity (va) of 0.2 logmar(6/9) or better. exclusion criteria * children under 4 years old and over 16 years old * strabismus and binocular vision anomalies. * alterations in eye fundus that the researcher consider necessary the patient exclution. * ocular pathology of the anterior segment (media opacity such as cataracts, glaucoma, aphakia, pseudophakia, uveitis, keratoconus or surface alterations), and any pathology of the posterior segment that prevents correct vision * amblyopia * previous eye surgery * systemic pathology (cardiopulmonary pathology, connective tissue alterations, neurological or psychiatric pathology) or baseline situation of the patient that does not allow the examination to be carried out (such as mental or psychomotor retardation) * previous myopia control treatments including orthokeratology, rigid contact lenses, bifocal or myopia control soft contact lenses, bifocal and multifocal ophthalmic lenses within 3 months prior to the study.
study of irinotecan and cetuximab versus irinotecan as second-line treatment in patients with metastatic, egfr-positive colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (egfr)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.


Eligibility criteria:
inclusion criteria: * histologically documented colorectal cancer which is egfr-positive by immunohistochemistry \[ihc\] (may be based on archival samples) and is metastatic. * prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer. * prior fluoropyrimidine-containing regimen (5-fluorouracil \[5-fu\], capecitabine, or uracil/tegafur \[uft\]), for the first-line treatment of metastatic disease. exclusion criteria: * a serious uncontrolled medical disorder that, in the opinion of the investigator, would impair the ability of the subject to receive protocol therapy * unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease * known or documented brain metastases
intrapartum epidural catheter displacement: dressing methods

Conditions: Analgesia, Obstetrical

Summary: failure of labor epidural is a well-recognized situation in obstetric anesthesia practice. incidence of epidural failure was shown to be 12% in a retrospective analysis of 19,259 deliveries. epidural migration has been documented in both the obstetric and non-obstetric settings. it has been argued that prevention of epidural displacement is a potential remedy to at least part of the incomplete or failed epidurals in obstetrics. purpose: the investigators propose this study to prospectively evaluate the efficacy of the three types of epidural catheter dressings that are currently in use in clinical practice, in terms of catheter migration, taking into consideration the influence of body mass index on this variable.

primary aim: the investigators will evaluate the efficacy of three different epidural catheter dressing systems in laboring patients. secondary aims: to compare the effect of different degrees of obesity measured by bmi, on epidural catheter migration and quality and failure of epidural labor analgesia. to evaluate the effect of time an indwelling catheter remains in place, level of insertion and patient's height on epidural catheter migration. hypothesis: the use of dressing with transparent tegadermtm plus catheter support pad dressing is superior to the dressing with tegadermtm plus steri-striptm bands, and to a dressing with tegadermtm only, for epidural catheter fixation in laboring obese and morbidly obese patients, in terms of catheter migration. epidural quality and failure and epidural catheter replacement in the labor analgesia setting.

Eligibility criteria:
inclusion criteria: 1. patients admitted to the labor and delivery unit at augusta university medical center who request epidural analgesia. 2. bmi \>30 kg/m2. 3. age older than 18 years old. exclusion criteria: 1. allergy to adhesive tape or to the components of the dressings used in the study. 2. preexisting sensory neurologic deficits affecting lower extremities. 3. patients taken to the operating room for cesarean section during the study period. 4. chronic pain conditions. 5. patients with intrathecal catheters.
a study of the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Conditions: Asthma; Coronary Artery Disease; Pulmonary Disease, Chronic Obstructive

Summary: this study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * subject has asthma or stable chronic obstructive pulmonary disease (copd). * subject has a diagnosis of coronary artery disease (cad) or risk factors for cad as determined by a current medical diagnosis of at least 2 of the following conditions: type 2 diabetes, hypertension, hypercholesterolemia, current or history of cigarette smoking (minimum 10 pack-years exposure) or obesity body mass index (bmi \> 30). * subject must abstain from smoking 3 hours prior and 8 hours post study drug administration. * subject must abstain from any intake of foods and beverages containing a methylated xanthine derivative (i.e. caffeine, theobromine, or methylxanthine) within 12 hours prior to study drug administration through the follow-up visit, as these foods may reduce the effects of regadenoson. * subject is able to safely abstain from theophylline for 12 hours prior to the day 1 visit, as determined by the investigator * asthma subject's frequency and severity of symptoms have remained unchanged within 30 days prior to study drug administration * asthma subject has fev1 ≥60% predicted * copd subject has fev1/fvc \< 0.70 exclusion criteria: * female subject who is pregnant, lactating or of childbearing potential who refuses to use a medically acceptable form of contraception until the follow-up visit is complete. * subject started on a course of corticosteroids, steroid combination with long-acting beta2-agonist (laba) (oral or inhaled) or anticholinergic, or has undergone a change in dose of such medications ≤ 30 days prior to study drug administration (subject on a stable dose of such medications for \> 30 days prior to study drug administration is allowed). * subject started leukotriene antagonists (e.g., montelukast), cromones (e.g., cromolyn sodium) or 5-lipoxygenase antagonists (e.g. zileuton or zyflo) or has undergone a change in dose of medications in these drug classes ≤ 7 days prior to study drug administration (subject on a stable dose of these medications for \> 7 days prior to study drug administration is allowed). * subject has a history of second or third degree heart block or sinus node dysfunction unless the subject has a functioning pacemaker. * subject has symptomatic hypotension (temporary and reversible conditions that no longer exist are allowed). * subject is allergic or intolerant to aminophylline. * subject has had a respiratory infection within 2 weeks prior to randomization. * subject has had surgery within 3 months prior to randomization.

Keywords: regadenoson cvt 3146 asthma coronary artery disease pulmonary disease, chronic obstructive
curcumin (diferuloylmethane derivative) with or without bioperine in patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: primary objectives: 1. to evaluate clinical tolerance and response to curcumin alone and in combination with bioperine in patients with multiple myeloma. 2. to compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + bioperine and evaluate the effect of bioperine on the bioavailability of curcumin. 3. to evaluate the biologic effects of curcumin alone and in combination with bioperine on the expression of nf-kb and related genes in the multiple myeloma (mm) cells.

curcumin, a yellow substance extracted from the plant curcuma longa, is commonly used as a food additive. it is a natural anti-inflammatory compound and has shown anti-tumor activity in the laboratory. bioperine is a pepper extract that increases the absorption of nutrient supplements. in this study, 6 patients at a time will be randomly assigned (as in the toss of a coin) to one of two groups of 3 patients each. one group (arm a) will receive curcumin alone. the other group (arm b) will receive curcumin in combination with bioperine. there is an equal chance of being in either group. while on study you may receive standard supportive care as appropriate. both of the study agents will be taken by mouth two times a day. each group will have five dose levels of curcumin, starting with the lowest dose. after 6 patients have been enrolled in the first level (3 in each arm), the next group will be treated at a new dose level. you will always receive the same dose during your treatment, which will continue for at least 12 weeks unless there is evidence that the disease has gotten worse or intolerable side effects occur. you may receive treatment up to one year depending on your response to treatment. you may be treated as outpatient and may receive your treatment at home. you will be asked to return to m. d. anderson every 4 weeks for evaluation and physical exam. this is an investigational study. a total of up to 30 evaluable patients will take part in the study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: * patients with multiple myeloma who have been previously untreated, are asymptomatic and without serious or imminent complications; or have relapsed or failed treatment with conventional therapy. * adequate hematologic, renal, and hepatic functions. * eastern cooperative oncology group (ecog) performance status 0, 1, or 2. exclusion criteria: * previously untreated patients with high tumor mass; symptomatic or impending fractures. * patients with significant cardiac disease. * patients with comorbid condition which renders patients at high risk of treatment complications. * history of significant neurological or psychiatric disorders.

Keywords: multiple myeloma diferuloylmethane derivative curcumin bioperine
research on the accurate diagnosis of urinary tract tumors and the development of kits

Conditions: Bladder Cancer; Urothelial Carcinoma

Summary: bladder cancer is the second most prevalent urological malignancy worldwide, with a high incidence and poor patient prognosis. achieving early diagnosis and intervention for bladder cancer is one of the most important ways to improve clinical management and patient prognosis. tumor exosomes can be released into biological fluids at an early stage of a tumor, and many studies have shown that exosomal rna can be used as a reliable biomarker to diagnose tumors in a non-invasive way. based on the clinical needs for early diagnosis of bladder cancer, we aim to screen several early diagnostic markers with potential predictive value, establish an early diagnostic model for bladder cancer, and validate the validity and reliability of this diagnostic model through a large-scale clinical cohort to complement the diagnosis of early-stage cancers and to improve the rate of early diagnosis of cancer.

in response to the clinical demand for accurate early diagnosis of bladder cancer, this project aims to gradually conduct in-depth research on precise early diagnosis of bladder cancer. this includes establishing key techniques for efficient and convenient enrichment of exosomes, identifying potential exosome biomarkers for bladder cancer based on bladder cancer transcriptome sequencing data, and conducting large-scale clinical cohort studies.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years with defined gender; 2. preoperative patients are preliminarily evaluated as bladder tumors by cystoscopy, fish, cytology, or imaging. exclusion criteria: 1. aged \<18 years; 2. post-operative or after anti-tumor treatment such as chemotherapy or immunotherapy 3. history of other malignant tumors 4. specimens with hemolytic conditions; 5. patients with incomplete, undocumented, and uncooperative data.
effect of yoga in reducing chemotherapy induced nausea and vomiting

Conditions: Breast Cancer; Malignant Female Reproductive System Neoplasm; Lymphomas; Chemotherapy-induced Nausea and Vomiting

Summary: * this randomized controlled three arm study compares the effects of a yoga intervention with jacobsons progressive muscle relaxation training and only standard of care in chemotherapy naive cancer patients. * this study will also assess the neurophysiological correlates of nausea and vomiting and assess if effects of intervention on nausea and vomiting outcomes are mediated by changes in gastric motility (electrogastrogram) or stress arousal (cardiac autonomic function and sympathetic skin response) or self reported anxiety.


Eligibility criteria:
inclusion criteria: * patients with gynecologic malignancies (breast, ovary) and lymphomas. * age between 30-70 years. * chemotherapy naïve. * high school education. exclusion criteria: * those with brain metastases * concurring medical condition likely to influence survival * uncontrolled diabetes and hypertension * gi metastases, peritoneal fluid, uraemia * neurological disorders such as parkinson's disease, myotonic dystrophy etc. * gi obstruction and past h/o abdominal surgeries. * cognitive impairments. * regular participation in a behavioral intervention/yoga in the last six months

Keywords: yoga chemotherapy nausea vomiting
healthy lifestyle behavior intervention for latino women

Conditions: Cardiovascular Diseases

Summary: the overall goal of this randomized controlled trial is to evaluate the effects of a community-based lifestyle behavior intervention (lsbi) that is designed to improve dietary habits and physical activity (pa), and reduce weight of latino women who are predominantly spanish-speaking immigrants. it is hypothesized that middle-aged overweight/obese latinas participating in a lsbi conducted by lay health advisors will demonstrate improved dietary habits, increased physical activity and a decrease in bmi compared to those in a control condition, women in the lsbi also are expected to demonstrate improvements in selected physiologic outcomes (waist circumference, blood pressure \[bp\], measures of cholesterol and blood sugar).

overweight/obesity and physical inactivity are two significant predictors of illness and death from cardiovascular (heart) disease (cvd) in latina adults. these risk factors may be reduced or eliminated through prevention efforts that focus on heart-healthy diets, weight reduction, and pa. the purpose of this study is to compare the effects of a 6-month community-based lifestyle behavior intervention (lsbi) conducted by lay health advisors and a control condition (disaster preparedness and home safety program) on lifestyle behaviors -dietary habits and physical activity(primary outcome) and selected physiologic outcomes (secondary outcomes) i.e., bmi, waist circumference, blood pressure, measures of cholesterol,and fasting blood sugar of latinas who are overweight/obese. the lsbi includes group education (8 classes) and individual teaching and coaching (8 contacts by home visits and telephone calls) delivered over a 6-month period. acceptability and feasibility of the intervention is evaluated through examination of women's retention rates and participation in classes and home visits.

Eligibility criteria:
inclusion criteria: * latina * 35 to 64 years of age * body mass index (bmi) \>25 * fluent in either spanish or english. exclusion criteria: * pregnant or planning to get pregnant in next year * history of myocardial infarction or stroke * currently under treatment for cancer * orthopedic or joint problems that would prohibit participation in physical activity * insulin-dependent diabetes

Keywords: hispanic/latina americans cardiovascular diseases obesity intervention